US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.53

+0.150010.87%

Post-market: 1.540.0100+0.65%19:30 EDT

Volume:561.19K

Turnover:865.44K

Market Cap:216.35M

PE:7.14

High:1.68

Open:1.38

Low:1.37

Close:1.38

52wk High:27.36

52wk Low:1.27

Shares:141.41M

Float Shares:41.01M

Volume Ratio:1.68

T/O Rate:1.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-11.08

PE(LYR):-0.26

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/VRXA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.53,"timestamp":1788465600000,"preClose":1.38,"halted":0,"volume":561194,"hourTrading":{"tag":"盘后","latestPrice":1.54,"preClose":1.53,"latestTime":"19:30 EDT","volume":1513,"amount":2308.672,"timestamp":1788478204826,"change":0.01,"changeRate":0.006536,"amplitude":0.013072},"delay":0,"changeRate":0.10869565217391315,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Closed","change":0.15,"latestTime":"09-03 16:00:00 EDT","open":1.38,"high":1.68,"low":1.3707,"amount":865436.1796378,"amplitude":0.22413,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788508800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.38,"preHourTrading":{"tag":"盘前","latestPrice":1.3706,"preClose":1.38,"latestTime":"09:24 EDT","volume":2254,"amount":3088.6683716,"timestamp":1788441852741,"change":-0.0094,"changeRate":-0.006812,"amplitude":0.003768},"postHourTrading":{"tag":"盘后","latestPrice":1.54,"preClose":1.53,"latestTime":"19:30 EDT","volume":1513,"amount":2308.672,"timestamp":1788478204826,"change":0.01,"changeRate":0.006536,"amplitude":0.013072},"volumeRatio":1.680969},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":1.680969,"shares":141407813,"dividePrice":0,"high":1.68,"amplitude":0.22413,"preClose":1.38,"low":1.3707,"week52Low":1.27,"pbRate":"-11.08","psRate":"7460.36","week52High":27.36,"institutionHeld":0,"latestPrice":1.53,"eps":0.2142,"divideRate":0,"volume":561194,"delay":0,"ttmEps":0.2142,"open":1.38,"prevYearClose":18.65,"prevWeekClose":1.35,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.44,"twentyDayClose":1.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-02","current":7.142857,"percent":0.777778,"low":-1.401348,"twenty":-1.336165,"median":-1.215321,"eighty":-0.427499,"high":-0.413162,"avg":-1.009416,"sd":0.397706,"marketCap":35304241},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-02","current":-0.430706,"twenty":-1.336165,"median":-1.215321,"eighty":-0.427499,"marketCap":35304241}],"updateTime":1788484628292},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664888755","title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888755","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888755?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207055,"startTime":"0","endTime":"0","summary":"Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650Veraxa Biotech CEO, director Christoph Rudiger Antz reported a purchase of 5,000 ordinary shares.The shares were bought at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5ghMkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530737","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:00","pubTimestamp":1787670008,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 25th, 2026, FinanceWire Following completion of the initial phase of its collaboration with OmniAb, VERAXA wil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","QLD","ONEQ","QQQE","BK4139","JEPQ","TQQQ","SQQQ",".IXIC","MNQmain","GPIQ","XBI","QQQM","QDTE","NDX","QYLG","VRXA","BK4585","IYW","NVIW.SI","QQQA","QQQ","QQQJ","BK4581","QQQY","FTEC","PSQ","NQmain","BK4588","TECS","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083312","title":"VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083312","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:00","pubTimestamp":1787590833,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 24th, 2026, FinanceWire VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","QYLG","PSQ","QQQE","BK4588","MNQmain",".IXIC","GPIQ","QQQY","QID","QLD","XBI","ONEQ","JEPQ","IYW","NQmain","QQQA","QQQM","SQQQ","TQQY","NVIW.SI","QDTE","NDX","FTEC","BK4581","QQQ","BK4139","VRXA","QQQJ","TECS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427591","title":"Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661427591?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VRXA\",params:#limit:6,delay:false,,,undefined,":[]}}